RXQ Compounding Secures Undisclosed Series A Funding

RXQ Compounding, LLC, an Athens, OH-based manufacturer of sterile and non-sterile medications licensed to ship to 38 states and Washington, D.C., secured a Series A funding of undisclosed amount.

The round was led by Ohio Innovation Fund (OIF). In conjunction with the funding, Bill Baumel, current managing director of OIF, will join the board of directors.

The company will use the funds to open a new FDA 503B outsourcing facility for pharmacy compounding, employing hundreds in the Appalachian area of Southeast Ohio.

Led by Chief Executive Officer Ed Zatta, RXQ manufactures sterile and non-sterile medications, including:
– Sterile and non-sterile injectables
– Veterinary medications
– Dermatologic creams and ointments
– Ophthalmic solutions
– Orthopedic steroids
– Custom production for hospitals.
It is currently licensed to ship to 38 states and Washington, D.C., with licenses for other states to come soon.

RXQ, which currently works with more than 500 customers, employs roughly 100 people in Columbus and Athens.



Join the discussion